

INTRODUCTION OF A NEW PRESENTATION OF HYALURONIC ACID FOR INTRAARTICULAR INFILTRATION

A. SÁNCHEZ RUIZ¹, I. VILLAMIZAR TOMAS¹, R. CLARAMUNT GARCÍA², E. PÉREZ CANO³, Y. JIMÉNEZ LÓPEZ³.
¹HOSPITAL ALTO GUADALQUIVIR, FARMACIA, ANDÚJAR- JAÉN, SPAIN. ²HOSPITAL VIRGEN DE ALTAGRACIA, PHARMACY, MANZANARES, SPAIN. ³HOSPITAL UNIVERSITARIO DE JAÉN, PHARMACY, JAÉN, SPAIN.
 andres.sanchez.ruiz2@gmail.com


BACKGROUND AND IMPORTANCE

In April 2020, the protocol for the use of intra-articular injections was updated within a multidisciplinary context with Pharmacy, Traumatology and Rehabilitation. Sodium hyaluronate 60mg/4ml (Hyalone®, high molecular weight) was included. According to the new protocol, the use of AdantOne® (low molecular weight hyaluronic acid) was approved for grades I-II according to the Kellgren-Lawrence index (IKL) or III-IV in cases where Hyalone® is not tolerated due to pain. Hyalone® was indicated for IKL grades II-III-IV.

AIM AND OBJECTIVES

To evaluate the healthcare and economic impact of the incorporation of a new presentation of hyaluronic acid in the intra-articular infiltration protocol of a regional hospital.

MATERIAL AND METHODS



Data was obtained from the electronic prescription program (number of patients, number of dispensations as well as cost per drug and total cost).

RESULTS

	PERIOD 1	PERIOD 2
Patients (n)	91	94
Adant One (% of patients)	85,10%	52,12%
Adant (% of patients)	14,89%	14,89%
Hyalone (% of patients)	-	32,97%
Adant One cost (€)	5.776,53 €	3.367,39 €
Adant cost (€)	495 €	363 €
Hyalone cost (€)	-	2.803,80 €
Total costs (€)	6.271,53 €	6.534,14 €

In period 1, the Rehabilitation service was the service that performed the most infiltrations (52.5% of the total patients treated with Adant One®) and 92.85% of the total patients treated with Adant®. In period 2, Adant One® was used in a similar way. In the case of Hyalone®, 96.77% was used by Rehabilitation Service

CONCLUSION AND RELEVANCE

The introduction of the new presentation of hyaluronic acid allows a better individualization of the treatment of intra-articular infiltrations and did not lead to a noticeable cost increase.

